-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals Reports New Preclinical Receptor Selectivity Findings for Pain Drug MIRA-55

PUBT·11/16/2026 21:05:24
Listen to the news
Mira Pharmaceuticals Reports New Preclinical Receptor Selectivity Findings for Pain Drug MIRA-55
  • MIRA Pharmaceuticals reported new preclinical findings supporting MIRA-55 as a potential non-opioid treatment for inflammatory pain.
  • Receptor screening showed selective activity distinct from conventional opioid and COX-inhibiting pain medicines.
  • Previously reported animal studies showed pain relief and reduced inflammation without significant THC-like motor impairment.
  • An investigational new drug submission is targeted for the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-052331), on November 16, 2026, and is solely responsible for the information contained therein.